Linsitinib showed significant efficacy in reducing proptosis in TED patients, with a 52% responder rate at 150mg BID. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback